Agomab Therapeutics director David R. Epstein buys 5,000 common shares for $44,500
AGMB•Director David R. Epstein bought 5,000 Agomab Therapeutics common shares at $8.90 each for $44,500, increasing his directly held stake to 15,000 shares.
1. Share purchase
Agomab Therapeutics director David R. Epstein bought 5,000 common shares at $8.90 each, for a total of $44,500. His directly held stake rose to 15,000 common shares.
